BIOGEN INC.

BIOGEN INC. (BIIB) — Investment Memo

🐂 The Bull Case (Warren's voice)

We don't buy "transitions"; we buy certainties. However, if there is a seed of a wonderful business here, it is this:

• The Rare Disease Pivot: Moving from the crowded MS market to rare diseases (like Friedreich's Ataxia via Reata) shifts the moat from competitive IP to monopolistic IP. Rare diseases often command higher pricing power and face fewer generic substitutes.
• The "Passive" Royalty Stream: Partner royalties are the purest form of economics—high margin, zero capex, and no operational headache. It is a toll bridge that requires no maintenance.
• Cash Flow Resilience: Despite the revenue slide, the business is still spitting out $2.1B in FCF. If management stops the "desperate search" and simply returns this cash to shareholders, the yield becomes a powerful tailwind.
• Attractive Range: This becomes a Berkshire play only if it is priced as a liquidating trust rather than a growth company. We would need it at a price where the current cash flow pays for the entire enterprise in 8–10 years, regardless of the pipeline.

🐻 The Bear Case (Charlie inverts)

“Show me where I’ll die and I won’t go there.” This business is walking toward a cliff in three different directions:

• The Melting Ice Cube: This is the classic "Patent Cliff" tragedy. When your revenue drops from $14.4B to $9.9B over six years, you aren't "transitioning"—you are evaporating. Replacing a multi-billion dollar franchise requires a "home run" drug; betting on a home run is gambling, not investing.
• The R&D Treadmill: Management is spending heavily on "cost saving" and "integration." In the pharma world, this usually means they are burning cash to stay in the same place. A company that must spend billions just to stop the bleeding is a business in structural decline.
• Regulatory Hostility: The Inflation Reduction Act (IRA) and Medicare price negotiations are the new "permanent impairment" risk. The government is now the primary buyer and is deciding the price. The "Regulatory Moat" is being dismantled by the very government that granted it.
• Most Likely Outcome: A slow, grinding decline into irrelevance over the next 5–7 years, where the rare disease growth is insufficient to offset the MS collapse.

💰 Valuation & Margin of Safety

The DCF provides a mathematical anchor, but math cannot fix a broken business model.

• Intrinsic value estimate: $205.56 per share
• 25% margin of safety entry: $154.17 (Conservative)
• 50% margin of safety entry: $102.78 (Buffett's ideal)
• Current Status: Trading near intrinsic value. It is fairly priced for a mediocre business, but expensive for a business with a shrinking revenue base. There is no margin of safety here to protect us from a pipeline failure.

Verdict: PASS

The business lacks a durable, compounding moat and behaves like a melting ice cube. Even at a "fair" price, we do not buy businesses in structural retreat. We will leave the "desperate search for a lifeline" to the speculators.